The Cardiovascular Research Technology (CRT) Meeting 2024 was held in Washington, D.C., USA from March 9th to 12th. Siran Bio was honored to be invited to present the research findings of SA016, a new drug for treating high blood pressure, at the CRT conference. On March 10th, Dr. Yang Zhiwei, the founder of Siran Bio, shared the non-clinical efficacy and safety of SA016 in Washington, which garnered great attention and recognition from the industry.

The Cardiovascular Research Technology (CRT) Meeting 2024 was held in Washington, D.C., USA from March 9th to 12th. Siran Bio was honored to be invited to present the research findings of SA016, a new drug for treating high blood pressure, at the CRT conference. On March 10th, Dr. Yang Zhiwei, the founder of Siran Bio, shared the non-clinical efficacy and safety of SA016 in Washington, which garnered great attention and recognition from the industry.

SA016 is an siRNA drug that utilizes N-acetylgalactosamine (GalNAc) conjugation technology to target angiotensinogen (AGT) mRNA. It can suppress the expression of AGT protein, thereby inhibiting the activity of the renin-angiotensin system (a key factor in the development of hypertension), achieving the goal of lowering blood pressure levels. This drug is primarily developed for the treatment of hypertension, and similar siRNA drugs like Zilebesiran have shown good antihypertensive effects in several Phase 2 clinical studies.

SA016 showed excellent activity in head-to-head studies with Zilebesiran both in vitro and in vivo. It demonstrated excellent AGT mRNA silencing effects in several in vitro cell systems, including cell lines, mokey primary hepatocytes, and human primary hepatocytes. In in vivo mouse models and crab-eating macaque studies, SA016 showed excellent AGT protein inhibition and long-lasting efficacy. Current data from crab-eating macaque studies indicate that SA016 can maintain activity for three months without rebound after a single administration. In spontaneous hypertensive crab-eating macaque models, SA016 showed excellent blood pressure control levels compared head-to-head with Zilebesiran. SA016 also showed superior safety in off-target studies in vitro and toxicological studies in vivo.

This year's CRT meeting placed a high emphasis on hypertension. Medtronic and Recor Medical used interventional treatment technologies to reduce signal transmission from renal nerves to the brain, which has a good long-term therapeutic effect on hypertension related to kidney disease. Siran Bio's SA016 has excellent complementary and combination opportunities with these emerging technologies.

The research findings of SA016 mark the international recognition of Siran Bio's innovation in the cardiovascular field. We look forward to sharing our research progress with global experts, achieving broader and deeper cooperation with the industry, and jointly promoting the rapid entry of SA016 into clinical trials and the market to benefit a wide range of hypertensive patients.

About CRT Meeting

The CRT conference in the United States is one of the world's leading conferences in interventional cardiology,focusing on progress and changes in the field of cardiovascular medicine. The annual CRT conference discusses new trial data, explores evidence-based research, and showcases the latest technologies that can be directly applied to clinical and academic practice.

About Siran Bio

Siran Bio was established in Suzhou Industrial Park in May 2022. It is a biotechnology company focused on the development of innovative siRNA drugs, co-founded by a top team of scientists in the field of nucleic acid therapy and industrialization experts.

The company has established an industry-leading nucleic acid drug technology platform with proprietary intellectual property rights, including eSAFE chemical modification technology and STORK liver and extrahepatic delivery technology platforms. Based on the leading technology platforms, the company has rapidly developed a pipeline of small nucleic acid drugs for antiviral, cardiovascular and metabolic diseases, autoimmune diseases, and central nervous system diseases. Two pipelines have entered the preclinical development stage.

The company is always patient-centered, committed to creating the best small nucleic acid drugs, addressing unmet clinical needs, and enhancing human health and happiness.